Semaglutide therapy and iatrogenic thyrotoxicosis
Levothyroxine is the backbone of hypothyroidism treatment. The dosage of levothyroxine varies; however, as an estimate, an average adult patient will require 1.6 micrograms per kilogram of body weight. We present the case of a patient with hypothyroidism, controlled on a stable dosage of levothyroxi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-07-01
|
| Series: | Endocrinology, Diabetes & Metabolism Case Reports |
| Subjects: | |
| Online Access: | https://edm.bioscientifica.com/view/journals/edm/2025/3/EDM-25-0065.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849721425525473280 |
|---|---|
| author | Maxim John Levy Barnett Sarah Eidbo Ana Rivadeneira |
| author_facet | Maxim John Levy Barnett Sarah Eidbo Ana Rivadeneira |
| author_sort | Maxim John Levy Barnett |
| collection | DOAJ |
| description | Levothyroxine is the backbone of hypothyroidism treatment. The dosage of levothyroxine varies; however, as an estimate, an average adult patient will require 1.6 micrograms per kilogram of body weight. We present the case of a patient with hypothyroidism, controlled on a stable dosage of levothyroxine, who subsequently began semaglutide therapy for obesity. She developed rapid weight loss and presented with palpitations as her main symptoms. Both clinical and biochemical analyses demonstrated new hyperthyroidism. With the weight loss, it was deemed that her levothyroxine dosage was no longer appropriate for her new weight and was over-suppressing her thyroid function (iatrogenic hyperthyroidism), requiring a dosage reduction. With follow-up, both clinical assessment and biochemical studies noted a reduction in the suppression of the thyroid axis. This case highlights the importance of considering a dosage reduction of levothyroxine when patients lose significant weight (such as with concurrent obesity medications), to prevent iatrogenic hyperthyroidism. |
| format | Article |
| id | doaj-art-10140e2bee154c83ae4d59e9e8770c7a |
| institution | DOAJ |
| issn | 2052-0573 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrinology, Diabetes & Metabolism Case Reports |
| spelling | doaj-art-10140e2bee154c83ae4d59e9e8770c7a2025-08-20T03:11:39ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732025-07-012025310.1530/EDM-25-00651Semaglutide therapy and iatrogenic thyrotoxicosisMaxim John Levy Barnett0Sarah Eidbo1Ana Rivadeneira2Internal Medicine, Jefferson Einstein Hospital, Philadelphia, Pennsylvania, USAInternal Medicine, Jefferson Einstein Hospital, Philadelphia, Pennsylvania, USAEndocrinology, Jefferson Einstein Hospital, Philadelphia, Pennsylvania, USALevothyroxine is the backbone of hypothyroidism treatment. The dosage of levothyroxine varies; however, as an estimate, an average adult patient will require 1.6 micrograms per kilogram of body weight. We present the case of a patient with hypothyroidism, controlled on a stable dosage of levothyroxine, who subsequently began semaglutide therapy for obesity. She developed rapid weight loss and presented with palpitations as her main symptoms. Both clinical and biochemical analyses demonstrated new hyperthyroidism. With the weight loss, it was deemed that her levothyroxine dosage was no longer appropriate for her new weight and was over-suppressing her thyroid function (iatrogenic hyperthyroidism), requiring a dosage reduction. With follow-up, both clinical assessment and biochemical studies noted a reduction in the suppression of the thyroid axis. This case highlights the importance of considering a dosage reduction of levothyroxine when patients lose significant weight (such as with concurrent obesity medications), to prevent iatrogenic hyperthyroidism.https://edm.bioscientifica.com/view/journals/edm/2025/3/EDM-25-0065.xmlthyroidobesitydiabetes |
| spellingShingle | Maxim John Levy Barnett Sarah Eidbo Ana Rivadeneira Semaglutide therapy and iatrogenic thyrotoxicosis Endocrinology, Diabetes & Metabolism Case Reports thyroid obesity diabetes |
| title | Semaglutide therapy and iatrogenic thyrotoxicosis |
| title_full | Semaglutide therapy and iatrogenic thyrotoxicosis |
| title_fullStr | Semaglutide therapy and iatrogenic thyrotoxicosis |
| title_full_unstemmed | Semaglutide therapy and iatrogenic thyrotoxicosis |
| title_short | Semaglutide therapy and iatrogenic thyrotoxicosis |
| title_sort | semaglutide therapy and iatrogenic thyrotoxicosis |
| topic | thyroid obesity diabetes |
| url | https://edm.bioscientifica.com/view/journals/edm/2025/3/EDM-25-0065.xml |
| work_keys_str_mv | AT maximjohnlevybarnett semaglutidetherapyandiatrogenicthyrotoxicosis AT saraheidbo semaglutidetherapyandiatrogenicthyrotoxicosis AT anarivadeneira semaglutidetherapyandiatrogenicthyrotoxicosis |